Cargando…

Angiotensin-Converting Enzyme Inhibitor Therapy Effects in Patients With Heart Failure With Preserved and Mid-Range Ejection Fraction

BACKGROUND: There is hypothesis that endothelial function enhancement is strongly associated with better outcome and functional class improvement in heart failure with preserved ejection fraction (HFpEF) and heart failure with mid-range ejection fraction (HFmrEF) patients. Perindopril is the only an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Safonova, Julia, Kozhevnikova, Maria, Danilogorskaya, Yulia, Zheleznykh, Elena, Zektser, Vita, Ilgisonis, Irina, Popova, Lyudmila, Khabarova, Natalia, Privalova, Elena, Belenkov, Yuri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683104/ https://www.ncbi.nlm.nih.gov/pubmed/34970367 http://dx.doi.org/10.14740/cr1322

Ejemplares similares

Relationship of Acylcarnitines to Myocardial Ischemic Remodeling and Clinical Manifestations in Chronic Heart Failure
por: Belenkov, Yuri N., et al.
Publicado: (2023)

Case Report: AL Amyloidosis Severe Restrictive Cardiomyopathy Associated With Multiple Myeloma—Diagnostic Difficulties
por: Kirichenko, Yulia Y., et al.
Publicado: (2022)

Association between prognosis and the use of angiotensin‐converting enzyme inhibitors and/or angiotensin II receptor blockers in frail patients with heart failure with preserved ejection fraction
por: Sunaga, Akihiro, et al.
Publicado: (2022)

Epicardial fat in heart failure patients with mid‐range and preserved ejection fraction
por: van Woerden, Gijs, et al.
Publicado: (2018)

Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction
por: Borrelli, Chiara, et al.
Publicado: (2019)

Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction
por: van Woerden, Gijs, et al.
Publicado: (2021)

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Angiotensin converting enzyme
por: Wong, Marty Kwok-Shing
Publicado: (2021)

Renin-Angiotensin Activation and Oxidative Stress in Early Heart Failure with Preserved Ejection Fraction
por: Negi, Smita I., et al.
Publicado: (2015)

Elevated mid-pregnancy plasma levels of angiotensin-converting enzyme 2 in women prior to the development of preeclampsia
por: Junus, Katja, et al.
Publicado: (2022)

Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction
por: Gilstrap, Lauren G., et al.
Publicado: (2017)

Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction: The Misleading Definition of the New Guidelines
por: Fedele, Francesco, et al.
Publicado: (2017)

Silent Cerebral Infarctions with Reduced, Mid-Range and Preserved Ejection Fraction in Patients with Heart Failure
por: Oliveira, Márcia Maria Carneiro, et al.
Publicado: (2018)

Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction
por: Son, Mi Kyoung, et al.
Publicado: (2020)

The serum angiotensin-converting enzyme 2 and angiotensin-(1-7) concentrations after optimal therapy for acute decompensated heart failure with reduced ejection fraction
por: Hisatake, Shinji, et al.
Publicado: (2020)

Residual Renal Function in Hemodialysis Patients: The Role of Angiotensin-Converting Enzyme Inhibitor in Its Preservation
por: Xydakis, Dimitris, et al.
Publicado: (2012)

The effects of enhancing angiotensin converting enzyme in myelomonocytes on ameliorating Alzheimer’s-related disease and preserving cognition
por: Danziger, Ron, et al.
Publicado: (2023)

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
por: Anker, Stefan D., et al.
Publicado: (2022)

Angiotensin-Converting Enzyme-2
por: Clarke, Nicola E., et al.
Publicado: (2013)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Perspectives in Genome-Editing Techniques for Livestock
por: Popova, Julia, et al.
Publicado: (2023)

Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism
por: Meurs, Kathryn M, et al.
Publicado: (2017)

Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
por: Vio, Carlos P., et al.
Publicado: (2020)

Clinical characteristics of hospitalized heart failure patients with preserved, mid‐range, and reduced ejection fractions in Japan
por: Shiga, Tsuyoshi, et al.
Publicado: (2019)

Gender disparities in heart failure with mid-range and preserved ejection fraction: Results from APOLLON study
por: Özlek, Bülent, et al.
Publicado: (2019)

Trends in cause‐specific readmissions in heart failure with preserved vs. reduced and mid‐range ejection fraction
por: Cui, Xiaotong, et al.
Publicado: (2020)

Left atrial diameter in heart failure with left ventricular preserved, mid-range, and reduced ejection fraction
por: Zhu, Ning, et al.
Publicado: (2019)

Assessment of right ventricular systolic function in heart failure with preserved, reduced and mid-range ejection fraction
por: Mostafa, Shaimaa
Publicado: (2019)

Left atrial function and maximal exercise capacity in heart failure with preserved and mid‐range ejection fraction
por: Maffeis, Caterina, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Tissue Specificity of Human Angiotensin I-Converting Enzyme
por: Kryukova, Olga V., et al.
Publicado: (2015)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
por: Malik, Jahanzeb, et al.
Publicado: (2021)

Use of angiotensin receptor blocker is associated with improved 1 year mortality in heart failure with mid‐range ejection fraction
por: Wang, Bin, et al.
Publicado: (2021)

Renin–angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2017)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
por: Adin, Darcy, et al.
Publicado: (2020)

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
por: ter Maaten, Jozine M., et al.
Publicado: (2020)

Angiotensin-Converting Enzyme Inhibitors and Angioedema
por: Sánchez-Borges, Mario, et al.
Publicado: (2010)

Angiotensin-converting Enzyme Genetic Polymorphism
por: Wiwanitkit, Somsri, et al.
Publicado: (2014)

The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction
por: Bielecka-Dabrowa, Agata, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_soh69hc69tmcsviv44mtkb1poa